Analysts Are Bullish On Seagen’s Catalyst-Rich Pipeline, Finding No Problem With No M&A
Seagen Inc (NASDAQ:SGEN) reported a Q4 EPS loss of $(0.80), better than the consensus of $(1.05) and $(0.95) a year…
Why Bellicum Pharmaceuticals Stock Is Plunging Today
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) announced the presentation of early Phase 1 results for BPX-601 at the American Society of Clinical Oncology…
Why Ambrx Biopharma Shares Are Surging Today?
Ambrx Biopharma Inc (NASDAQ:AMAM) announced initial data from its ongoing Phase 1 APEX-01 trial of ARX517, Ambrx’s proprietary anti-PSMA ADC, in…
Applied Therapeutics Reveals Pivotal Study Data In Hereditary Neuropathy
Applied Therapeutics Inc (NASDAQ:APLT) announced sorbitol reduction data from the ongoing global Phase 3 INSPIRE trial of oral AT-007 in approximately…
Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate
Aura Biosciences Inc (NASDAQ:AURA) announced the presentation of interim Phase 2 safety and efficacy data of belzupacap sarotalocan (bel-sar;…
AstraZeneca And Merck Announced Results From The Final Analysis Of Overall Survival From Phase 3 Propel Trial Of Lynparza Plus Abiraterone And Prednisone Or Prednisolone (Abi/Pred), Compared To Placebo Plus Abi/Pred. Did Not Reach Statistical Significa…
Median OS was 42.1 months for the LYNPARZA plus abi/pred arm versus 34.7 months for the placebo plus abi/pred arm, representing a 7.4-month absolute difference in median OS versus a standard of care
NexImmune Shares Are Ripping Today – Read Why
NexImmune Inc (NASDAQ:NEXI) stock is up premarket after the company said that new preclinical data showed that AIM ACT T cells…
Intelligent Bio Solutions Has Filed A 513(G) Submission With The FDA For Its Intelligent Fingerprinting Drug Screening Cartridge
The submission will allow Intelligent Bio Solutions to determine the most suitable FDA regulatory pathway as part of the Company's strategy for expansion into the U.S. market.
The Intelligent Fingerprinting
Sermonix Pharmaceuticals’ Lasofoxifene, Will Be Evaluated In A New Study Arm Of The Ongoing I-SPY Endocrine Program Sponsored By Quantum Leap Healthcare Collaborative, In Newly Diagnosed ER+ Invasive Cancer, Lasofoxifene Was In-Licensed From Ligand Pha…
The arm is part of the I-SPY 2 Endocrine Optimization Platform (EOP), which is focused on patients with clinically high-risk (stage 2/3) estrogen receptor-positive (ER+)/HER2- breast cancer, but the molecularly
Pharming Provides Update On European Medicines Agency Regulatory Review Of Leniolisib For APDS In Europe; Decided To Shift Its Assessment Of The Marketing Authorisation Application For Leniolisib To A Standard Review Timetable
EMA Marketing Authorisation Application for leniolisib changed to standard review timetable
LEIDEN, Netherlands, Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the